Antimycotic Azoles (all routes except local only) updated on 01-29-2025

Craniosynostosis

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S17734
R74879		 Howley - Fluconazole, 2016 Craniosynostosis 1st trimester case control unexposed (general population or NOS) Adjustment: No Fluconazole not specified or mixed dose 1.21 [0.15;10.07] C 1/7   1,597/13,203 1,598 7
ref
S17735
R74917		 Molgaard-Nielsen - Fluconazole, 2013 Craniosynostosis 1st trimester population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes Fluconazole not specified or mixed dose 1.07 [0.48;2.39] 6/7,352   716/968,236 722 7,352
ref
S17725
R74797		 Carter - Miconazole, 2008 Craniosynostosis 1st trimester case control unexposed (general population or NOS) Adjustment: No 0.55 [0.13;2.27] C 2/41   445/5,180 447 41
ref
Total 3 studies 0.94 [0.48;1.82] 2,767 7,400
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Howley - Fluconazole, 2016Howley - Fluconazole, 2016 1.21[0.15; 10.07]1,598710%ROB confusion: criticalROB selection: criticalROB classification: criticalROB missing: lowROB mesure: criticalROB reporting: moderate Molgaard-Nielsen - Fluconazole, 2013Molgaard-Nielsen - Fluconazole, 2013 1.07[0.48; 2.39]7227,35268%ROB confusion: seriousROB selection: lowROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Carter - Miconazole, 2008Carter - Miconazole, 2008 0.55[0.13; 2.27]4474122%ROB confusion: criticalROB selection: criticalROB classification: criticalROB missing: moderateROB mesure: moderateROB reporting: moderate Total (3 studies) I2 = 0% 0.94[0.48; 1.82]2,7677,4000.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.07[0.48; 2.39]7227,352 -NAMolgaard-Nielsen - Fluconazole, 2013 1 case control studiescase control studies 0.70[0.21; 2.28]2,045480%NAHowley - Fluconazole, 2016 Carter - Miconazole, 2008 2 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 0.94[0.48; 1.82]2,7677,4000%NAHowley - Fluconazole, 2016 Molgaard-Nielsen - Fluconazole, 2013 Carter - Miconazole, 2008 3 Tags Adjustment   - No  - No 0.70[0.21; 2.28]2,045480%NAHowley - Fluconazole, 2016 Carter - Miconazole, 2008 2   - Yes  - Yes 1.07[0.48; 2.39]7227,352 -NAMolgaard-Nielsen - Fluconazole, 2013 1 Fluconazole not specified or mixed doseFluconazole not specified or mixed dose 1.09[0.51; 2.30]2,3207,3590%NAHowley - Fluconazole, 2016 Molgaard-Nielsen - Fluconazole, 2013 2 All studiesAll studies 0.94[0.48; 1.82]2,7677,4000%NAHowley - Fluconazole, 2016 Molgaard-Nielsen - Fluconazole, 2013 Carter - Miconazole, 2008 30.25.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 0.94[0.48; 1.82]2,7677,4000%NAHowley - Fluconazole, 2016 Molgaard-Nielsen - Fluconazole, 2013 Carter - Miconazole, 2008 30.510.01.0